Propionate meditech

Budesonide/formoterol maintenance and reliever therapy did not significantly reduce time to first severe exacerbation (primary variable) versus CBP ( P   =   ). However, patients in this group experienced 15% fewer exacerbations ( versus /patient/year; P   =   ) and used 27% less ICS ( P   <   ). Odds of remaining well controlled (ACQ   ≤) over 6 months were higher with budesonide/formoterol maintenance and reliever therapy versus CBP (45% versus 41%, odds ratio [OR] ; P   <   ) while risk of remaining uncontrolled decreased (25% versus 29%, OR ; P   <   ).

Propionate meditech

propionate meditech

Media:

propionate meditechpropionate meditechpropionate meditechpropionate meditechpropionate meditech

http://buy-steroids.org